<DOC>
	<DOCNO>NCT03019406</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety profile neoGAA patient infantile-onset Pompe disease ( IOPD ) previously treat alglucosidase alfa . Secondary Objective : To characterize pharmacokinetic profile neoGAA evaluate preliminary efficacy neoGAA comparison alglucosidase alfa .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy NeoGAA Administered Every Other Week Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa</brief_title>
	<detailed_description>The duration study per patient 3 year consist 14-day screening period , 25-week treatment period , 120-week extension period , 4-week post-treatment observation period .</detailed_description>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Inclusion criterion : The patient confirm GAA enzyme deficiency tissue source . The patient reach legal age majority define local regulation , patient 's legal guardian ( ) must provide sign informed consent prior perform studyrelated procedure . If patient legally minor per local regulation , assent shall obtain patient , applicable . The patient ( patient 's legal guardian patient legally minor define local regulation ) must ability comply clinical protocol . The patient &lt; 18 year old . The patient , female childbearing potential , must negative serum pregnancy test ( betahuman chorionic gonadotropin ) must breastfeed screening/baseline . The patient cardiomyopathy time diagnosis : ie , leave ventricular mass index ( LVMI ) equivalent mean age specific LVMI plus 2 standard deviation . The patient receive stable dose alglucosidase alfa regularly minimum 6 month immediately prior study entry . For participant Stage 1 : The patient document evidence clinical decline least 1 follow parameter related Pompe Disease NOT related intercurrent illness assess Investigator : respiratory function , motor skill , and/or cardiac parameter . For participant Stage 2 : The patient document evidence suboptimal clinical response least 1 follow parameter related Pompe Disease NOT related intercurrent illness assess Investigator : respiratory function , motor skill , and/or new onset ptosis . Exclusion criterion : The patient high antibody titer alglucosidase alfa . The patient high risk severe allergic reaction neoGAA . The patient require prohibit concomitant medication ( e.g. , immune modulatory treatment betablockers ) duration study . The patient previously participate ACT14132 study cohort . Female patient childbearing potential protect highly effective contraceptive method birth control and/or unwilling unable test pregnancy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>